½ÃÀ庸°í¼­
»óǰÄÚµå
1772699

°áÇÙ ¹é½Å Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼®, ¹é½Å À¯Çüº°, Ä¡·á À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, ¿¬·ÉÃþº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)

Tuberculosis Vaccine Treatment Market Size, Share, and Growth Analysis, By Vaccine Type (BCG, Recombinant), By Treatment Type (Preventive, Therapeutic), By End-User, By Age Group, By Region - Industry Forecast 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 191 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°áÇÙ ¹é½Å Ä¡·á ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 5¾ï ´Þ·¯, 2024³â 5¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 7¾ï 2,000¸¸ ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£(2025-2032³â) CAGRÀº 4.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

°áÇÙ ¹é½Å Ä¡·á ½ÃÀåÀº °áÇÙ À¯º´·ü Áõ°¡¿Í °áÇÙ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ ¿¹¹æ¹ý, ƯÈ÷ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±³À° ÀÌ´Ï¼ÅÆ¼ºê¿Í Á¤ºÎ ÁÖµµÀÇ °øÁߺ¸°Ç Ä·ÆäÀÎÀº °áÇÙ¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í °áÇÙ°ú °ü·ÃµÈ À§Çè°ú ¿¹¹æÁ¢Á¾ÀÇ ÀÌÁ¡À» °­Á¶ÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀüÀ¸·Î Áø´Ü ´É·Â°ú ¹é½Å Á¢Á¾ ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î °áÇÙÀÇ Á¶±â ¹ß°ß°ú °³ÀÔÀÌ ½¬¿öÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î °áÇÙ ¹é½Å Ä¡·á´Â Àü ¼¼°è º¸°Ç »óȲ¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖÀ¸¸ç, ½ÃÀå ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

¼­·Ð

  • Á¶»ç ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀå ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

ÁÖ¿ä ¿ä¾à

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ Five Forces ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • Áß¿ä ¼º°ø ¿äÀÎ
  • °æÀï Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå »ýŰè
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • »ç·Ê ¿¬±¸

°áÇÙ ¹é½Å Ä¡·á ½ÃÀå ±Ô¸ð : ¹é½Å À¯Çüº°&CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • BCG
  • ÀçÁ¶ÇÕ
  • »ý¾àµ¶È­
  • ºÒȰ¼ºÈ­

°áÇÙ ¹é½Å Ä¡·á ½ÃÀå ±Ô¸ð : Ä¡·á À¯Çüº°&CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ¿¹¹æ
  • Ä¡·á

°áÇÙ ¹é½Å Ä¡·á ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº°&CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • º´¿ø
  • Ŭ¸®´Ð
  • ¿¬±¸±â°ü
  • ±âŸ

°áÇÙ ¹é½Å Ä¡·á ½ÃÀå ±Ô¸ð : ¿¬·ÉÃþº°&CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ¼Ò¾Æ
  • ¼ºÀÎ

°áÇÙ ¹é½Å Ä¡·á ½ÃÀå ±Ô¸ð : Áö¿ªº°&CAGR(2025-2032)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • ÁÖ¿ä 5°³»ç ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
  • ÃÖ±Ù ½ÃÀå µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • ±â¾÷ »ó¼¼
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ±â¾÷ ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâ Àü³â´ëºñ ºñ±³(2022-2024³â)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Xykon
  • Merck and Co
  • Pfizer
  • Aeras
  • Antabio
  • KNCV Tuberculosis Foundation
  • Inovio Pharmaceuticals
  • Bavarian Nordic
  • Bill and Melinda Gates Foundation
  • Vaxart
  • Serum Institute of India
  • Emergent BioSolutions
  • GlaxoSmithKline

°á·Ð°ú Á¦¾È

LSH 25.07.23

Global Tuberculosis Vaccine Treatment Market size was valued at USD 0.5 billion in 2023 and is poised to grow from USD 0.52 billion in 2024 to USD 0.72 billion by 2032, growing at a CAGR of 4.1% during the forecast period (2025-2032).

The tuberculosis vaccine treatment market is experiencing significant growth due to the increasing prevalence of tuberculosis and the heightened awareness surrounding the disease. As more cases emerge, the demand for effective prevention methods, particularly vaccines, is intensifying. Educational initiatives and government-led public health campaigns are pivotal in raising awareness about tuberculosis, emphasizing the risks associated with it and the benefits of vaccination. Furthermore, advancements in healthcare infrastructure are improving diagnostic capabilities and the accessibility of vaccination services, facilitating early detection and intervention for tuberculosis. Collectively, these factors are driving robust demand in the market, positioning tuberculosis vaccine treatments as a crucial element in the global health landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tuberculosis Vaccine Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tuberculosis Vaccine Treatment Market Segments Analysis

Global Tuberculosis Vaccine Treatment Market is segmented by Vaccine Type, Treatment Type, End-User, Age Group and region. Based on Vaccine Type, the market is segmented into BCG, Recombinant, Live Attenuated and Inactivated. Based on Treatment Type, the market is segmented into Preventive and Therapeutic. Based on End-User, the market is segmented into Hospitals, Clinics, Research Institutes and Others. Based on Age Group, the market is segmented into Pediatric and Adult. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tuberculosis Vaccine Treatment Market

The rise in awareness surrounding tuberculosis treatments plays a crucial role in driving the global tuberculosis vaccine treatment market. As public knowledge of TB risks and the significance of vaccination grows, it fosters greater acceptance and demand for vaccines. Health education initiatives and outreach efforts contribute to a better understanding of prevention methods, encouraging timely immunization. This heightened awareness supports government initiatives and financial backing, ultimately leading to improved vaccine coverage. Such developments are particularly vital in regions heavily burdened by TB, where effective control measures are essential to combat the disease and boost the tuberculosis vaccine market's growth.

Restraints in the Global Tuberculosis Vaccine Treatment Market

The Global Tuberculosis Vaccine Treatment market faces significant challenges due to the limited effectiveness of the BCG vaccine in preventing pulmonary tuberculosis, particularly in adolescents and adults. While the BCG vaccine is effective against severe forms of TB in young children, its efficacy diminishes with age and offers inconsistent protection in the adult population. This reduced effectiveness leads to a decline in confidence and demand for the vaccine, highlighting a crucial need for innovative and enhanced vaccine options. Consequently, this limitation hampers market growth and complicates global efforts to control and manage tuberculosis effectively.

Market Trends of the Global Tuberculosis Vaccine Treatment Market

The global tuberculosis vaccine treatment market is witnessing a transformative trend centered around the development of novel vaccines that aim to address the limitations of the traditional BCG vaccine. As researchers explore innovative methodologies-including live attenuated, subunit, viral-vectored, and mRNA vaccine approaches-there is a growing emphasis on enhancing efficacy against both active and latent TB, as well as drug-resistant strains. Advances in genetic engineering and immunology are facilitating this clinical progress, fostering optimism for the emergence of more effective and long-lasting TB vaccines in the coming years, thereby reshaping strategies for tuberculosis prevention and control worldwide.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Case Studies

Global Tuberculosis Vaccine Treatment Market Size by Vaccine Type & CAGR (2025-2032)

  • Market Overview
  • BCG
  • Recombinant
  • Live Attenuated
  • Inactivated

Global Tuberculosis Vaccine Treatment Market Size by Treatment Type & CAGR (2025-2032)

  • Market Overview
  • Preventive
  • Therapeutic

Global Tuberculosis Vaccine Treatment Market Size by End-User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Clinics
  • Research Institutes
  • Others

Global Tuberculosis Vaccine Treatment Market Size by Age Group & CAGR (2025-2032)

  • Market Overview
  • Pediatric
  • Adult

Global Tuberculosis Vaccine Treatment Market Size & CAGR (2025-2032)

  • North America (Vaccine Type, Treatment Type, End-User, Age Group)
    • US
    • Canada
  • Europe (Vaccine Type, Treatment Type, End-User, Age Group)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Vaccine Type, Treatment Type, End-User, Age Group)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Vaccine Type, Treatment Type, End-User, Age Group)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Vaccine Type, Treatment Type, End-User, Age Group)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Xykon
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck and Co
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aeras
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Antabio
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • KNCV Tuberculosis Foundation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Inovio Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bavarian Nordic
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bill and Melinda Gates Foundation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vaxart
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Serum Institute of India
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Emergent BioSolutions
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦